Valproate modulates the activity of multidrug resistance efflux pumps, as a chemoresistance factor in gastric cancer cells

Hosseini, Sayedeh Azimeh; Mirzaei, Seyed Abbas; Kermani, Shahriar; Yaghoobi, Hajar

doi:10.1007/s11033-024-09284-0

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 409 The absence of cyclin B1 causing cell cycle arrest in the G2/M phase is now recognized as a contributing factor to resistance against ADC‐induced cell death. 410 Therefore, assessing cyclin B1 induction could serve as a pharmacodynamic predictor in ADC treatment.…”

Section: Adc Resistance Mechanisms and Intervention Strategiesmentioning

confidence: 99%

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

He,

Zeng,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) consist of monoclonal antibodies that target tumor cells and cytotoxic drugs linked through linkers. By leveraging antibodies’ targeting properties, ADCs deliver cytotoxic drugs into tumor cells via endocytosis after identifying the tumor antigen. This precise method aims to kill tumor cells selectively while minimizing harm to normal cells, offering safe and effective therapeutic benefits. Recent years have seen significant progress in antitumor treatment with ADC development, providing patients with new and potent treatment options. With over 300 ADCs explored for various tumor indications and some already approved for clinical use, challenges such as resistance due to factors like antigen expression, ADC processing, and payload have emerged. This review aims to outline the history of ADC development, their structure, mechanism of action, recent composition advancements, target selection, completed and ongoing clinical trials, resistance mechanisms, and intervention strategies. Additionally, it will delve into the potential of ADCs with novel markers, linkers, payloads, and innovative action mechanisms to enhance cancer treatment options. The evolution of ADCs has also led to the emergence of combination therapy as a new therapeutic approach to improve drug efficacy.

show abstract

Section: Adc Resistance Mechanisms and Intervention Strategiesmentioning

confidence: 99%

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

He,

Zeng,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters

Lu,

Jin

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Resistance to chemotherapeutic agents poses a significant challenge in cancer treatment, particularly with doxorubicin, a widely used drug for various cancers, including breast cancer, leukaemia, osteosarcoma, and gastrointestinal cancers. This review aims to elucidate the critical role of microRNAs (miRNAs) in the development of doxorubicin resistance, focusing on their interactions with ATP-binding cassette (ABC) transporters. Despite extensive research, the molecular mechanisms governing doxorubicin resistance still need to be completed, particularly regarding the regulatory influence of miRNAs on ABC transporter expression. By analyzing current literature, this review identifies a notable gap: the lack of comprehensive insight into how specific miRNAs modulate the expression and activity of ABC transporters in cancer cells, contributing to doxorubicin resistance. We systematically examine recent findings on the interplay between miRNAs and ABC transporters, providing a detailed assessment of potential therapeutic strategies that leverage miRNA modulation to overcome drug resistance. Ultimately, this review underscores the significance of integrating miRNA research into existing therapeutic frameworks to enhance the efficacy of doxorubicin in cancer treatment.

show abstract

Valproate modulates the activity of multidrug resistance efflux pumps, as a chemoresistance factor in gastric cancer cells

Cited by 2 publications

References 27 publications

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters

Contact Info

Product

Resources

About